Improving Safety by Basic Computerizing Outpatient Prescribing
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Indiana
-
Indianapolis, Indiana, United States, 46202
- Wishard Helath Services
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Partner's Healthcare
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- provider practicing at sites implementing order entry with basic clinical decision support using either the longitudinal medical record (LMR) or Medical Gopher
Exclusion Criteria:
- provider or practice unwilling to participate
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Placebo Comparator: Routine Care
Usual care of patients in the ambulatory setting
|
Routine Care
|
|
Experimental: Basic Clinical Decision Support
Providers use basic clinical decision support
|
The computerized physician order entry (CPOE) intervention provides physicians with a menu of medications from the formulary, default doses, and a range of potential doses for each medication.
Physicians were required to enter dosage, route, and frequency for all orders.
Also, CPOE ensured that all orders were legible and included the prescribing physician's signature.
For a number of medications, the system displayed relevant laboratory results on the screen at the time of ordering.
Other features included consequent orders, which are orders that should follow from other orders, and drug-allergy checking, drug-drug interaction checking, and drug-laboratory checking.
This included checking for the most frequent drug allergies, about 80 carefully selected drug-drug interactions, and several drug-laboratory combinations
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Adverse Drug Events
Time Frame: 6 months
|
Adverse drug events are measured through use of a computerized surveillance system augmented by focused structured human review
|
6 months
|
|
Medical Errors
Time Frame: 6 months
|
Medical Errors are identified through a computerized surveillance system with structured human review
|
6 months
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: David Bates, MD, Brigham and Women's Hospital
- Principal Investigator: Joseph M Overhage, MD, PhD, Indiana University
- Principal Investigator: Tejal Gandhi, MD, Brigham and Women's Hospital
- Principal Investigator: Andrew Seger, PharmD, Brigham and Women's Hospital
Publications and helpful links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimated)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 0008-44
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.